U.S. Markets open in 8 hrs 21 mins
  • S&P Futures

    3,674.00
    +9.50 (+0.26%)
     
  • Dow Futures

    30,011.00
    +79.00 (+0.26%)
     
  • Nasdaq Futures

    12,509.50
    +47.25 (+0.38%)
     
  • Russell 2000 Futures

    1,852.10
    +4.90 (+0.27%)
     
  • Crude Oil

    46.49
    +0.85 (+1.86%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.10
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2155
    +0.0006 (+0.0486%)
     
  • 10-Yr Bond

    0.9200
    0.0000 (0.00%)
     
  • Vix

    21.28
    +0.11 (+0.52%)
     
  • GBP/USD

    1.3455
    +0.0002 (+0.0148%)
     
  • USD/JPY

    103.9270
    +0.0670 (+0.0645%)
     
  • BTC-USD

    19,251.46
    -6.12 (-0.03%)
     
  • CMC Crypto 200

    378.09
    +3.68 (+0.98%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,761.10
    -48.27 (-0.18%)
     

Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

·2 min read

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 1:10 p.m. ET.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005748/en/

Contacts

Investor and Media Contact:
Bicycle Therapeutics
Maren Killackey
maren.killackey@bicycletx.com
+1-617-203-8300